secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-10-01T20:08:04+00:00
Accession:  0001193125-26-410663
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Perspective Therapeutics (CATX) files updated corporate presentation covering four 212Pb radiopharmaceutical programs
--------------------------------------------------------------------------------

- Perspective Therapeutics filed an updated corporate presentation (Exhibit 99.1) dated October 1, 2026, signed by CFO Joel Sendek.
- Presentation cites a combined $45B+ addressable solid tumor market for VMT-α-NET, VMT01, PSV359 and PSV594.
- VMT-α-NET Phase 1/2a data in SSTR2+ neuroendocrine tumors targeted for ASCO 2026; safety data shown for 68 treated patients.
- VMT01 preliminary anti-tumor activity observed at the 3.0 mCi dose in melanoma; PSV359 shows improved tumor retention against FAP-α.
- CCK2R81 is highlighted as a potential first-in-class agent in medullary thyroid cancer and selected solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/0001193125-26-410663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/catx-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-410663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer